Leahy et al. [59] demonstrated no significant difference in CR, RFS and/or OS between pediatrics patients receiving anti-CD19 CAR T therapy with CNS R/R ALL, versus those without CNS disease. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.